NTBC and alkaptonuria.
作者信息
Anikster Y, Nyhan W L, Gahl W A
出版信息
Am J Hum Genet. 1998 Sep;63(3):920-1. doi: 10.1086/302027.
Abstract
摘要
相似文献
1
NTBC and alkaptonuria.NTBC与黑尿症
Am J Hum Genet. 1998 Sep;63(3):920-1. doi: 10.1086/302027.
2
Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC).用4-羟基苯丙酮酸双加氧酶抑制剂（NTBC）治疗两名患有I型遗传性酪氨酸血症和长期肾病的儿童。
J Inherit Metab Dis. 1996;19(2):234-8. doi: 10.1007/BF01799438.
3
Plasma antioxidant capacity in two cases of tyrosinaemia type 1: one case treated with NTBC.两例1型酪氨酸血症患者的血浆抗氧化能力：一例接受NTBC治疗。
J Inherit Metab Dis. 1995;18(2):123-6. doi: 10.1007/BF00711745.
4
Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).I型酪氨酸血症与NTBC（2-（2-硝基-4-三氟甲基苯甲酰基）-1,3-环己二酮）
J Inherit Metab Dis. 1998 Aug;21(5):507-17. doi: 10.1023/a:1005410820201.
5
NTBC as palliative treatment in chronic tyrosinaemia type I.NTBC作为1型慢性酪氨酸血症的姑息治疗方法。
J Inherit Metab Dis. 1999 Jun;22(5):665-6. doi: 10.1023/a:1005594416973.
6
Pregnancy in an NTBC-treated patient with hereditary tyrosinemia type I.接受NTBC治疗的I型遗传性酪氨酸血症患者怀孕。
J Pediatr Gastroenterol Nutr. 2015 Jan;60(1):e5-7. doi: 10.1097/MPG.0b013e3182a27463.
7
A novel therapeutic trial of homogentisic aciduria in a murine model of alkaptonuria.在黑尿症小鼠模型中对尿黑酸尿症进行的一项新型治疗试验。
J Hum Genet. 1999;44(2):79-84. doi: 10.1007/s100380050114.
8
The role of nitisinone in tyrosine pathway disorders.尼替西农在酪氨酸途径疾病中的作用。
Curr Rheumatol Rep. 2014 Nov;16(11):457. doi: 10.1007/s11926-014-0457-0.
9
Promising new treatment for type I tyrosinemia.I型酪氨酸血症的前景广阔的新疗法。
J Pediatr Gastroenterol Nutr. 1993 Oct;17(3):340-1.
10
Alkaptonuria.尿黑酸尿症
N Engl J Med. 2003 Apr 3;348(14):1408; author reply 1408. doi: 10.1056/NEJM200304033481421.
引用本文的文献
1
Patient-reported outcomes and functional assessments of patients with Alkaptonuria in a 3-year Nitisinone treatment trial.在为期 3 年的尼替西农治疗试验中，对 alkaptonuria 患者的患者报告结局和功能评估。
Mol Genet Metab. 2024 Sep-Oct;143(1-2):108562. doi: 10.1016/j.ymgme.2024.108562. Epub 2024 Aug 3.
2
Alkaptonuria.黑尿症
Nat Rev Dis Primers. 2024 Mar 7;10(1):16. doi: 10.1038/s41572-024-00498-x.
3
Clinical development innovation in rare diseases: overcoming barriers to successful delivery of a randomised clinical trial in alkaptonuria-a mini-review.罕见病临床开发创新：克服尿黑酸症随机临床试验成功交付的障碍——小型综述。
Orphanet J Rare Dis. 2023 Jan 4;18(1):1. doi: 10.1186/s13023-022-02606-0.
4
Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuria-An approach using statistical modelling.比较2毫克和10毫克尼替西农治疗尿黑酸尿症——一种使用统计建模的方法
JIMD Rep. 2021 Nov 11;63(1):80-92. doi: 10.1002/jmd2.12261. eCollection 2022 Jan.
5
Vitiligo, alkaptonuria, and nitisinone-A report of three families and review of the literature.白癜风、尿黑酸尿症与尼替西农——三个家族的报告及文献综述
JIMD Rep. 2021 Jun 14;61(1):25-33. doi: 10.1002/jmd2.12225. eCollection 2021 Sep.
6
Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre.尼替西农治疗后黑酸尿症中褐黄病色素沉着的逆转：来自英国国家黑酸尿症中心的数据分析
JIMD Rep. 2020 Jun 22;55(1):75-87. doi: 10.1002/jmd2.12137. eCollection 2020 Sep.
7
Assessment of Thyroid Function in Patients With Alkaptonuria.尿黑酸症患者甲状腺功能评估。
JAMA Netw Open. 2020 Mar 2;3(3):e201357. doi: 10.1001/jamanetworkopen.2020.1357.
8
Alkaptonuria: A case report.黑尿症：一例病例报告。
Indian J Ophthalmol. 2017 Jun;65(6):518-521. doi: 10.4103/ijo.IJO_337_16.
9
Alkaptonuric ochronosis.尿黑酸尿性褐黄病
J Res Med Sci. 2015 Oct;20(10):1018-9. doi: 10.4103/1735-1995.172800.
10
Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with Alkaptonuria.尿黑酸尿症患者血清中尼替西农浓度与其对尿黑酸和酪氨酸影响的关系
JIMD Rep. 2015;24:21-7. doi: 10.1007/8904_2015_412. Epub 2015 Mar 13.
Zotero 插件